MARKET

SNGX

SNGX

Soligenix Inc
NASDAQ
0.3599
-0.0459
-11.31%
After Hours: 0.3478 -0.0121 -3.36% 18:44 05/15 EDT
OPEN
0.3969
PREV CLOSE
0.4058
HIGH
0.3977
LOW
0.3471
VOLUME
635.04K
TURNOVER
--
52 WEEK HIGH
6.23
52 WEEK LOW
0.2800
MARKET CAP
3.71M
P/E (TTM)
-0.1685
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SNGX last week (0504-0508)?
Weekly Report · 4d ago
Soligenix reports Q1 EPS (28c) vs. (97c) last year
TipRanks · 05/08 12:43
Soligenix GAAP EPS of $0.28
Seeking Alpha · 05/08 11:44
Soligenix Q1 net loss narrows on lower expenses
Reuters · 05/08 11:39
Soligenix Q1 EPS $(0.28), Inline
Benzinga · 05/08 11:38
Soligenix Q1 FY26 net loss narrows to $2.8 million; reports no revenue
PUBT · 05/08 11:34
*Soligenix: After Discontinuation of FLASH2 Study, Company's Ability to Continue as Going Concern Will Be Dependent Upon Ability to Develop and Commercialize Its Remaining Pipeline Assets >SNGX
Dow Jones · 05/08 11:34
*Soligenix 1Q Loss/Shr 28c >SNGX
Dow Jones · 05/08 11:32
More
About SNGX
Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).

Webull offers Soligenix Inc stock information, including NASDAQ: SNGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNGX stock methods without spending real money on the virtual paper trading platform.